- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01108770
Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia
Evaluation of Phenotypic and Genetic Properties in Male Subjects With Hypohidrotic Ectodermal Dysplasia and Their Family Members
Study Overview
Status
Conditions
Detailed Description
This study is designed to obtain information from male subjects with HED and unaffected male control subjects. The study will consist of the standardized collection of data from HED medical history questionnaires and non-invasive tests. A subset of subjects will undergo genetic testing. All data will be collected from families attending the 2010 NFED Family Conference, July 22-24, 2010, in Colorado Springs, CO.
Since HED is a rare disease, it is difficult to obtain reliable data on a sufficient number of subjects in any one region. The NFED Family Conference is a location where families affected with HED come together, and therefore, presents an ideal location to obtain data needed to design future studies. As the procedures are non-invasive and are designed to take a relatively short period of time, subjects can participate in this study while attending the NFED Family Conference.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80906
- Cheyenne Mountain Resort
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Registered and attending the 2010 NFED Family Conference;
- One year of age or greater;
Conform to one of the following requirements for providing informed consent:
- if more than 18 years of age, subjects must provide signed informed consent;
- if less than 18 years of age and it is determined that the subject is capable of providing assent, both the assent of the subject and consent of the parent(s) or guardian of that subject must be granted. Under this condition, both parents of the subject should give their permission, unless 1 parent is deceased, unknown, incompetent, or not available;
- if the subject is incapable of providing assent, the consent of the parent(s) or guardian of the subject must be granted. Under this condition, both parents should give their consent, unless 1 parent is deceased, unknown, incompetent, or not available.
Subjects must meet one of the following criteria:
- Male subjects of original gender with the clinical characteristics of HED, including at least a history of decreased sweating and either abnormal teeth (fewer permanent teeth, teeth are smaller than average and often have conical crowns), and/or sparseness of scalp and body hair;
- Healthy male controls, i.e. either unaffected male family members or unaffected male volunteers.
Exclusion Criteria:
- Known hypersensitivity to pilocarpine or pilocarpine-like muscarinic agonists.
- Presence of pacemakers.
- Subjects who are not able or are not willing to comply with the procedures of this protocol.
- Subjects with any major medical problem that will prevent them from participating in this study.
Study Plan
How is the study designed?
Cohorts and Interventions
Group / Cohort |
---|
HED affected males
|
Unaffected male controls
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization of skin properties in HED affected male subjects compared with healthy controls
Time Frame: Two assessments conducted once during study day.
|
The primary objective of this descriptive study is to use skin assessment techniques to characterize skin properties in male subjects affected by HED compared with healthy controls including determination of the number of sweat glands and the rate of sweating.
|
Two assessments conducted once during study day.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Collecting demographic information and clinical status in male subjects affected by HED using a medical questionnaire.
Time Frame: Collected once during study day.
|
Collected once during study day.
|
Testing for the presence of ectodysplasin A (EDA) gene mutations in a subset of subjects enrolled in this study.
Time Frame: Collected once during study day.
|
Collected once during study day.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ECP-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ectodermal Dysplasia
-
Edimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal DysplasiaUnited States
-
Edimer PharmaceuticalsActive, not recruitingX-linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy
-
University Hospital ErlangenEdimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal DysplasiaGermany
-
EspeRare FoundationIqvia Pty Ltd; Pierre Fabre MedicamentRecruitingX-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)United States, Spain, France, Germany, Italy, United Kingdom
-
Edimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal Dysplasia | Hypohidrotic Ectodermal DysplasiaUnited States
-
Edimer PharmaceuticalsCompletedX-linked Hypohidrotic Ectodermal Dysplasia | Hypohidrotic Ectodermal DysplasiaSpain
-
Edimer PharmaceuticalsCompletedX-Linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy
-
Edimer PharmaceuticalsCompletedX Linked Hypohidrotic Ectodermal DysplasiaUnited States
-
Edimer PharmaceuticalsCompletedX-Linked Hypohidrotic Ectodermal DysplasiaUnited States, United Kingdom, France, Germany, Italy
-
Edimer PharmaceuticalsCompletedHypohidrotic Ectodermal Dysplasia | X-Linked Hypohidrotic Ectodermal DysplasiaUnited States